The global non-alcoholic steatohepatitis clinical trials market size accounted for USD 2,831 million in 2024 and is expected to exceed around USD 5,621 million by 2034, growing at a CAGR of 7.1% from 2024 to 2034.
The non-alcoholic steatohepatitis clinical trials market refers to the production, distribution, and use of non-alcoholic steatohepatitis (NASH), which is a type of liver disease in which fat builds up in the liver of people who drink little or no alcohol. The NASH is an advanced form of non-alcoholic fatty liver disease (NAFLD). The purpose of NASH clinical trial research is to create a registry of patients having or at risk for metabolic liver disease for investigations into the molecular pathogenesis of liver cancer, cirrhosis, and end-stage liver disease. There is a high demand for these clinical trials in expanded access studies, observational studies, and interventional studies, which is driving the growth of the non-alcoholic steatohepatitis clinical trials market.
However, the risk factors of the market include limited treatment options, market competition, regulatory hurdles, and diagnosis complexities, which can limit the growth of the market. The future scope of the market includes increasing patient awareness, collaborative research initiatives, non-invasive diagnostic tools, and the development of new therapies that will help the growth of the non-alcoholic steatohepatitis clinical trials market.
Published by Ajit Bansod
